InvestorsHub on MSN
Biodesix advances MRD monitoring programs with Bio-Rad and Thermo Fisher
Biodesix, Inc. (NASDAQ:BDSX) reported progress in two collaborative Molecular Residual Disease (MRD) monitoring programs designed to detect circulating tumor DNA (ctDNA) in blood following cancer ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The U.S. Government plans to cut the annual budget allocated to the NIH by 40% in 2026. This decision could have an adverse effect on the operations of Bio-Rad. Bio-Rad projects 0.5% revenue growth ...
Bio-Rad is filing fewer patents year after year, which suggests that it is struggling to innovate and develop new products and services. The company is lagging its peers with a negative ROE, and net ...
BIO's Clinical Diagnostics strength and international reach support growth, while China weakness, geopolitics and FX remain ...
Bio-Rad Laboratories has delivered a sharp mix of outcomes for long term holders, with the stock down about 52.9% over 5 years even as shorter term returns have turned positive. This puts the ...
Bio-Rad Laboratories (NYSE:BIO) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table provides a quick ...
Bio-Rad Laboratories (NYSE:BIO) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement. Analysts estimate that Bio-Rad ...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Dr. Andrew Last, ...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an ...
The stock price of Bio-Rad Laboratories (NYSE: BIO), a life science research and clinical diagnostic products company, has seen a 10% rise over the last twenty-one trading days, while it is up 30% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results